Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 901–1,000 of 1,002
Associations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
“In hypoxia, for instance, hypoxia enhances the secretion of CCL28 by tumor cells in a HIF-1α-dependent mode, which enhances the recruitment of CCR10 + T reg cells to the tumor site, thus inhibiting the functions of cytotoxic T cells and accelerating tumor growth [62, 63].”
BackgroundMulti-omic analyses of m5C readers reveal their characteristics and immunotherapeutic proficiency
Xu, R. J., Wang, Y., & Kuang, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-52110-7 · Cited by 14
Kashkooli, F. M., Mirala, F., Tehrani, M. H. H., Alirahimi, M., Souri, M., Golzaryan, A., Kar, S., & Soltani, M. (2025) · WIREs Mechanisms of Disease · doi:10.1002/wsbm.70000 · Cited by 19
Ikeuchi, N., Igata, F., KINOSHITA, E., KAWABATA, T., TAN, I., OSAKI, Y., Otsuka, R., On, R., Ikeda, T., Nakao, A., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16210 · Cited by 14
Wan, Z., Zuo, X., Wang, S., Zhou, L., Wen, X., Yao, Y., Song, J., Gu, J., Wang, Z., Liu, R., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6316 · Cited by 15
Advancing Cancer Treatment Through Nanotechnology Driven Immunotherapy for Pancreatic Cancer
Nair, S. T., Kamalasanan, K., Sneha, S., Pavithran, K., & Harb, H. (2023) · ACS Applied Nano Materials · doi:10.1021/acsanm.3c03454 · Cited by 14
Cold to Hot: Tumor Immunotherapy by Promoting Vascular Normalization Based on PDGFB Nanocomposites
Ma, S., Tian, Z., Liu, L., Zhu, J., Wang, J., Zhao, S., Zhu, Y., Zhu, J., Wang, W., Jiang, R., et al. (2023) · Small · doi:10.1002/smll.202308638 · Cited by 14
Complex micelles with the bioactive function of reversible oxygen transfer
Shen, L., Zhao, L., Qu, R., Huang, F., Gao, H., An, Y., & Shi, L. (2014) · Nano Research · doi:10.1007/s12274-014-0651-4 · Cited by 13
“treatments because of hypoxia [7–9].”
Deng, W., Xu, M., Meng, Q., Li, Z., Qiu, X., Yin, S., Sun, D., Dai, C., & Liu, Y. (2019) · Rheumatology · doi:10.1093/rheumatology/kez112 · Cited by 13
RetractedEinstein, D. J., & McDermott, D. F. (2017) · PubMed · Cited by 13
Yu, Y., Wang, Y., Wang, Y., Wang, X., Liu, Y., Wang, J., Du, C., Wang, L., Li, M., Luo, F., et al. (2016) · Scientific Reports · doi:10.1038/srep34239 · Cited by 14
Self-citationEssentially all models are wrong, but some are useful
Simard, J. M. (2015) · Neurology · doi:10.1212/wnl.0000000000001769 · Cited by 13
Characterizing the extracellular matrix transcriptome of cervical, endometrial, and uterine cancers
Cook, C. J., Miller, A. E., Barker, T. H., Di, Y., & Fogg, K. C. (2022) · Matrix Biology Plus · doi:10.1016/j.mbplus.2022.100117 · Cited by 12
“DEMGs that were stage significant in all three gynecological cancer types included PRL (prolactin, critical to mammary gland development and lactation through regulation of estrogen receptors [61]; upregulated in CESC and UCEC, but downregulated in UCS), CCL28 (promotes angiogenesis in response to hypoxia [28]; upregu…”
BackgroundNeutralization of excessive CCL28 improves wound healing in diabetic mice
Chen, Z., Haus, J. M., DiPietro, L. A., Koh, T. J., & Minshall, R. D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1087924 · Cited by 17
“A previous study demonstrated that elevation of CCL28 facilitated homing of Tregs that foster ovarian tumor angiogenesis (Facciabene et al., 2011).”
BackgroundBeckers, C., Vasilikos, L., Sánchez‐Fernández, A., Moor, L., & Pruschy, M. N. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.110039 · Cited by 13
Zhao, Y., Tang, G., Li, J., Bian, X., Zhou, X., & Feng, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-69020-3 · Cited by 15
“CCR10 and CXCR2 were generally expressed at low levels by Tregs, while CXCR4 was highly and universally expressed by Tregs, with higher expression in Treg1 cells than in Treg2 cells.”
BackgroundInfluentialHuo, M., Adeerjiang, Y., Abulitipu, A., Khan, U., Li, X.-X., Zhang, L., Tian, Y., Jiang, S., Xu, C., Chao, X.-Z., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1325575 · Cited by 12
Self-citationLiu, Y., Zhang, Y., Yang, X., Lang, S., Zhu, Y., Song, J., Zhu, Y., Xu, H., Pei, P., Zhu, H. X., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113792 · Cited by 13
Multi-scenario photoacoustic endoscopy for in vivo functional imaging
Liang, X. Q., Zhao, Y., Li, L., Sun, H., Qin, W., Li, T., Guo, H., Qi, W., & Xi, L. (2025) · Photoacoustics · doi:10.1016/j.pacs.2025.100750 · Cited by 12
“Cancer progression is often characterized by vascular proliferation and abnormal blood oxygen levels [51].”
Boutet, M., Nishitani, K., Couturier, N., Erler, P., Zhang, Z., Militello, A. M., de Miranda, M. C., Barbieux, E., Guillen, E., Leavenworth, J. W., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.07.008 · Cited by 12
Effects of TSLP on obstetrical and gynecological diseases
Zhang, Y., & Jin, L. (2016) · American Journal of Reproductive Immunology · doi:10.1111/aji.12612 · Cited by 12
Rocha, S., Basto, A. P., Ijsselsteijn, M. E., Teles, S. P., Azevedo, M. M., Gonçalves, G., Gullo, I., Almeida, G. M., Maqueda, J. J., Oliveira, M. I., et al. (2021) · Cancers · doi:10.3390/cancers13030421 · Cited by 14
Chafe, S. C., Riaz, N., Burugu, S., Gao, D., Leung, S. C. Y., Lee, A. F., Lee, C., Dedhar, S., & Nielsen, T. O. (2021) · Cancers · doi:10.3390/cancers13051022 · Cited by 12
“Secondly, hypoxia-induced chemokine (CCL28) production [56] and FOXP3 transcriptional upregulation enriches for FOXP3+ T regulatory cells, which play a crucial role in self-tolerance [57].”
BackgroundHSA-MnO 2 - 131 I Combined Imaging and Treatment of Anaplastic Thyroid Carcinoma
Yan, Z., Zhang, X., Liu, Y., Shen, Y., Li, N., Jia, Q., Ji, Y., Zhang, P., Zhao, L., & Meng, Z. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221106557 · Cited by 14
“A hypoxic microenvironment increases the chance of tumor occurrence and leads to local tumor infiltration and distant metastasis by accumulation of extracellular adenosine in tumors.(28,29) MnO2 acts as a catalyst to react with the endogenous H2O2 of the tumor microenvironment and generate O2.”
BackgroundZheng, X., Xu, H., Lin, T., Tan, P., Xiong, Q., Yi, X., Qiu, S., Yang, L., Shen, B., Ai, J., et al. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105727 · Cited by 12
Ma, K., Chen, S., Chen, X., Zhao, X., & Yang, J. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02060-4 · Cited by 14
A Bloody Conspiracy— Blood Vessels and Immune Cells in the Tumor Microenvironment
Terrassoux, L., Claux, H., Bacari, S., Meignan, S., & Furlan, A. (2022) · Cancers · doi:10.3390/cancers14194581 · Cited by 13
Gao, F., Dong, J., Xue, C., An, L., Zhang, T., Wang, W.-J., Ou, C., & Dong, X. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101831 · Cited by 12
Gao, W., Wu, J., Chen, X., Lin, L., Fei, X., Shen, K., & Huang, O. (2019) · Journal of Cancer · doi:10.7150/jca.29337 · Cited by 12
Li, X., Li, D., Shi, Q., Huang, X., & Ju, X. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10074 · Cited by 14
“In addition to the immunosuppressive function of Tregs, emerging evidence suggests a link between angiogenesis and the accumulation of Tregs at tumor sites (4,5).”
BackgroundInfluentialThe impact of hypoxia on oncolytic virotherapy
Guo, Z. S. (2011) · Virus Adaptation and Treatment · doi:10.2147/vaat.s17832 · Cited by 20
“Another mechanism is that tumor hypoxia also promotes the recruitment of regulatory T cells through induction of expression of chemokine (C-C motif) ligand 28, which in turn promotes tumor tolerance and angiogenesis.(63) In summary, hypoxia-induced changes lead to the diminished innate and adaptive immunity against ca…”
Pampeno, C., Opp, S., Hurtado, A. M., & Meruelo, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052925 · Cited by 11
Liu, Y., Lin, H., Zhong, W., Zeng, Y., Zhou, G., Chen, Z., Huang, S., Zhang, L., & Liu, X. (2024) · Clinical Oral Investigations · doi:10.1007/s00784-024-05645-y · Cited by 13
“Consequently, strategies aimed at remodeling the tumor-immune microenvironment are emerging as promising approaches to augment the anti-tumor immune response [24, 25].”
BackgroundSelf-citationGe, J., Chen, J., Shen, Q. “., Zheng, X., Chen, X., Shi, L., Chen, L., & Xu, B. (2024) · Cancer Control · doi:10.1177/10732748241251580 · Cited by 13
Dai, S., Peng, Y., Wang, G., Chen, C., Chen, Q., Yin, L., Yan, H., Zhang, K., Tu, M., Lu, Z., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01358-7 · Cited by 14
Sun, J., Wang, D., Wei, Y., Wang, D., Ji, Z., Sun, W., Wang, X., Wang, P., Paccione, N., Larrarte, E., et al. (2024) · Nanoscale · doi:10.1039/d4nr04454a · Cited by 13
Targeting Cancer: Microenvironment and Immunotherapy Innovations
Padzińska-Pruszyńska, I. B., Taciak, B., Kiraga, Ł., Smolarska, A., Górczak, M., Kucharzewska, P., Kubiak, M., Szeliga, J., Matejuk, A., & Król, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413569 · Cited by 12
Wu, S., Ho, C., Yang, J. C., Yu, S., Lin, K., Lin, S., Liao, B.-C., Yang, C., Lin, Y., Yu, C., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.70149 · Cited by 14
Emerging innovations in nanomedicine for cancer immunotherapy
Shah, J. R., Kapoor, D. U., & Prajapati, B. G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106584 · Cited by 12
Recent Progress and Potential of G4 Ligands in Cancer Immunotherapy
Lin, J., Gong, Z., Lu, Y., Cai, J., Zhang, J., Tan, J., Huang, Z., & Chen, S. (2025) · Molecules · doi:10.3390/molecules30081805 · Cited by 13
“Additionally, the recruitment of regulatory T cells (Tregs) [8,9] and myeloid-derived suppressor cells (MDSCs) into the TME contributes significantly to immune suppression, reducing the effectiveness of anti-tumor responses (Figure 1) [10–12].”
Li, Y., Yang, L., & Zd, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104883 · Cited by 14
A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma
Nie, Y., Li, J., Wu, W., Guo, D., Lei, X., Zhang, T., Wang, Y., Mao, Z., Zhang, X., & Song, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706915 · Cited by 11
“Treg cells regulate the expression of CTLA-4, PD-1, and TGF-b to directly bind with the corresponding receptors on target cells and inhibit the expression of the important cytokines interferon-gamma (IFNg), tumor necrosis factor-a (TNF-a), and IL-2 that affect T cells.”
BackgroundInfluentialSaba, N. F., Vijayvargiya, P., Vermorken, J. B., Rodrigo, J. P., Willems, S. M., Zidar, N., de Bree, R., Mäkitie, A. A., Wolf, G. T., Argiris, A. E., et al. (2022) · Cancers · doi:10.3390/cancers14051202 · Cited by 11
“This environment leads to an increased expression of CCL28 and SDF-1, which induces an immunosuppressed TME by promoting tolerance in T regulatory cells, MDSCs, and TAMs [56,57].”
BackgroundChen, Z., Haus, J. M., Chen, L., Jiang, Y., Sverdlov, M. S., DiPietro, L. A., Xiong, N., Wu, S., Koh, T. J., & Minshall, R. D. (2022) · Diabetes · doi:10.2337/db21-1108 · Cited by 16
Lu, Y., Feng, N., Du, Y., & Yu, R. (2022) · Nanomaterials · doi:10.3390/nano12162832 · Cited by 12
“The resulting hypoxia not only promotes tumor progression and metastasis by changing the gene expression of tumor cells but confers resistance to therapy [34,35], thereby creating a vicious cycle.”
BackgroundPlasma protein alterations during human large vessel stroke: A controlled comparison study
Hazelwood, H. S., Frank, J. A., Maglinger, B., McLouth, C. J., Trout, A. L., Turchan-Cholewo, J. T., Stowe, A. M., Pahwa, S. S., Dornbos, D., Fraser, J. F., et al. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105421 · Cited by 12
Combinatorial approach of immuno‐proton therapy in cancer: Rationale and potential impact
Gaikwad, U., Bajpai, J., & Jalali, R. (2023) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13966 · Cited by 16
“20 21–23 Tumor hypoxia also attenuates antigen-presenting cells (APCs) with resultant decreased antigen presentation, which helps tumor cells to acquire resistance to T-cell mediated killing.”
BackgroundHypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Sadri, M., Najafi, A., Rahimi, A. R., Behranvand, N., Kazemi, M. H., Khorramdelazad, H., & Falak, R. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110470 · Cited by 12
Singh, R. K., Srivastava, P., & Manna, P. P. (2024) · Medical Oncology · doi:10.1007/s12032-023-02289-y · Cited by 12
“Intratumoral delivery of an anti-CCR10 immu-notoxin elevates the immune response in a mouse model of cancer by preventing the interaction between CCL28 and CCR10 and decreases the number of Treg cells in the TME [131].”
Zhang, H., Li, Y., Liu, G., & Chen, X. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05508-1 · Cited by 14
“Moreover, the stress induces Treg production that can both enhance tumor angiogenesis and inhibit anti-tumor responses (Facciabene et al. 2011).”
BackgroundBrain tumor immunotherapy: seeing the brain in the body
Lampson, L. A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.11.007 · Cited by 12
Renin–Angiotensin System in the Tumor Microenvironment
Nakamura, K., Okuyama, R., & Kawakami, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-50224-9_7 · Cited by 12
Spatial interplay of tissue hypoxia and T-cell regulation in ductal carcinoma in situ
Sobhani, F., Muralidhar, S., Hamidinekoo, A., Hall, A. H. S., King, L. M., Marks, J. R., Maley, C. C., Horlings, H. M., Hwang, E. S., & Yuan, Y. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00419-9 · Cited by 11
Chen, S., Wei, H., Zhao, W., Jiang, W., Ning, R., Zhou, S., Tan, L., Wang, H., Su, C., He, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1059995 · Cited by 13
“For example, in the presence of C-C Motif Chemokine Ligand 22 (CCL22) and C-CMotif Chemokine Ligand 28 (CCL28), Tregs are further promoted into the tumor cells (30).”
BackgroundTherapy with CD4+CD25+ T regulatory cells – should we be afraid of cancer?
Gliwiński, M., Piotrowska, M., Iwaszkiewicz‐Grześ, D., Urban‐Wójciuk, Z., & Trzonkowski, P. (2019) · Współczesna Onkologia · doi:10.5114/wo.2019.84110 · Cited by 13
“Hence, advanced tumors with hypoxic regions and/or building their own microcirculation can attract Treg cell migration using this axis [50].”
Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer
Martínez, A., Delord, J., Ayyoub, M., & Devaud, C. (2020) · Cancers · doi:10.3390/cancers12071761 · Cited by 11
Targeted therapy of tumour microenvironment by gold nanoparticles as a new therapeutic approach
Mahhengam, N., Kazemnezhad, K., Budi, H. S., Ansari, M. J., Bokov, D. O., Suksatan, W., Thangavelu, L. P., & Siahmansouri, H. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2032095 · Cited by 12
“environment similar to that found in the TME significantly release VEGF-A, leading to the formation of endothelial-tube [80,81].”
BackgroundFragment-based drug discovery of small molecule ligands for the human chemokine CCL28
Zhou, A. L., Jensen, D. R., Peterson, F. C., Thomas, M. A., Schlimgen, R. R., Dwinell, M. B., Smith, B. C., & Volkman, B. F. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.02.004 · Cited by 10
“[6] Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, et al.”
BackgroundSmall molecule inhibitors targeting regulatory T cells for cancer treatment
García‐Díaz, N., Wei, Q., & Taskén, K. (2023) · European Journal of Immunology · doi:10.1002/eji.202350448 · Cited by 10
“In ovarian and liver cancer, CCR10 + TI-Tregs are attracted to the TME by hypoxia in a CCL28-dependent manner [20, 21].”
BackgroundThe influence of biophysical niche on tumor-associated macrophages in liver cancer
Zhang, Y., Rao, Y., Lu, J., Wang, J., Ker, D. F. E., Zhou, J., & Wang, D. M. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000569 · Cited by 10
“[164] 167] In the TME, strong compressive forces can directly or indirectly influence immune cells, including macrophages.”
BackgroundThe tumor ecosystem: Rewiring an open, systemically integrated network for therapeutic gain
Chiodelli, P., Papait, A., Agoni, L., Quaglia, F., Silini, A. R., & Parolini, O. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119047 · Cited by 12
Immune dysregulation in endometriosis: the T cell perspective
Sisnett, D. J., Zutautas, K. B., Vo, D. H. N., Ravishanker, A., Holmes, J. P., Wodz, A., & Tayade, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1712360 · Cited by 12
“In an ovarian cancer study, Tregs were recruited to tumor sites via CCL28, where they contributed excess VEGFA and promoted tumor angiogenesis (123).”
Enabling T Cell Recruitment to Tumours as a Strategy for Improving Adoptive T Cell Therapy
Cadilha, B. L., Dorman, K., Rataj, F., Endres, S., & Kobold, S. (2017) · European Oncology & Haematology · doi:10.17925/eoh.2017.13.01.66 · Cited by 12
Mudassar, F., Shen, H. M., Cook, K. M., & Hau, E. K. C. (2022) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13416 · Cited by 10
“A positive correlation between CCL28 and HIF-1a expression was observed in ovarian cancer, and this was linked to poor patient prognosis.(90) Similarly, hypoxia-induced recruitment of Tregs is found to be a negative prognostic factor in HCC and basal-like breast cancer.”
BackgroundA Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
Meyo, M. T., Chen, J., Goldwasser, F., Hirsch, L., & Huillard, O. (2022) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s263832 · Cited by 13
“Tumor hypoxia also promotes the recruitment of regulatory T cell via the expression of the chemokine CC-chemokine ligand 28.(62) VEGF pathway inhibitors could modulate tumor immunosuppression mediated by indirect effects through endothelial cells and hypoxia.”
BackgroundComprehensive Explorations of CCL28 in Lung Adenocarcinoma Immunotherapy and Experimental Validation
Su, X., Wang, G., Zheng, S., Ge, C., Kong, F., & Wang, C. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s399193 · Cited by 10
Update on Radiotherapy Changes of Nasopharyngeal Carcinoma Tumor Microenvironment
Zhu, D., Su, C., Li, J. J., Li, A. W., Luv, Y., & Fan, Q. (2023) · World Journal of Oncology · doi:10.14740/wjon1645 · Cited by 10
“Treg cells can also be driven by HIF-1α-dependent transcription factors (FoxP3) or attracted by the cytokine spectrum in the tumor bed microenvironment [75].”
BackgroundImmune Responses against Disseminated Tumor Cells
Peng, L., Zhang, Y., & Wang, Z. (2021) · Cancers · doi:10.3390/cancers13112515 · Cited by 11
“Tregs are selectively trended into tumor tissues by tumor cells in a CCL22- and CCL28-dependent manner; subsequent Treg-induced secretion of VEGF-A by cancer cells promotes endothelial cell proliferation [53].”
BackgroundGilloteaux, J., Jamison, J. M., Neal, D. R., Summers, J. L., & Taper, H. S. (2012) · Ultrastructural Pathology · doi:10.3109/01913123.2012.708472 · Cited by 10
Su, X., Sun, T., Li, M., Xia, Y., Li, M., Wang, D., Lu, F., Ye, J., & Ji, C. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03588-0 · Cited by 10
Khalil, M., & Tsao, M. (2025) · Cancers · doi:10.3390/cancers17132199 · Cited by 10
“Secondly, at the same time, enhanced angiogenesis also increases the abundance of pro-tumour lymphocytes by secreting chemokines that recruit regulatory T cells and MDSCs to the tumour [168] and promote polarization of tumour-associated macrophages to the M2-like phenotype [169].”
Ding, Y., Wang, Z., Zhou, F.-M., Chen, C., & Qin, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.987302 · Cited by 13
Streptavidin-Saporin: Converting Biotinylated Materials into Targeted Toxins
Ancheta, L. R., Shramm, P. A., Bouajram, R., Higgins, D., & Lappi, D. A. (2023) · Toxins · doi:10.3390/toxins15030181 · Cited by 10
Hamada, Y., Tanoue, K., Kita, Y., Tanabe, K., Hokonohara, K., Wada, M., Hozaka, Y., Oi, H., Nakayama, C., Higashi, M., et al. (2023) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2023.2194011 · Cited by 10
Cellular crosstalk of regulatory T cells in pancreatic ductal adenocarcinoma
Shi, X., Liu, H., & Liang, Z. (2023) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000135 · Cited by 10
“[99] The investigation of the impacts of Tregs on endothelial cells in PDAC might expand the functionality of PDAC-infiltrating Tregs.”
BackgroundDoes SARS-CoV-2 Induce IgG4 Synthesis to Evade the Immune System?
Rubio‐Casillas, A., Redwan, E. M. M. M., & Uversky, V. N. (2023) · Biomolecules · doi:10.3390/biom13091338 · Cited by 12
“One such component was hypoxia, a characteristic and a significant contributor Accordingly, significant levels of lactic acid are found in COVID ‐ 19 patients [48] and in tumors, where it has been shown to impact Treg function [49]. to severe COVID-19 [46] that can enhance activity [47].”
Kemel, H., Benguedouar, L., Boudjerda, D., Menadi, S., Çaçan, E., & Sifour, M. (2024) · Medical Oncology · doi:10.1007/s12032-024-02396-4 · Cited by 9
“The process by which antioxidants inhibit angiogenesis involves their capacity to reduce oxidative stress and interfere with various signaling pathways that promote blood vessel formation [8, 46].”
Khalil, R. G., Mohammed, D. A., Hamdalla, H. M., & Ahmed, O. M. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156834 · Cited by 11
Tumor Microenvironment: Obstacles and Opportunities for T Cell–Based Tumor Immunotherapies
Hu, M., Zhao, Y., Zhang, N., Gong, F., Zhang, W., Dong, C., Dai, J., & Wang, J. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-24-0747 · Cited by 11
Novel avenues in immunotherapies for colorectal cancer
Pardieck, I. N., Jawahier, P. A., Swets, M., van de Velde, C. J. �., & Kuppen, P. J. K. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1122522 · Cited by 9
“bute to angiogenesis, resulting in tumor growth.[112] In general, Tregs have been found to promote primary tumor progression and are associated with poor clinical outcomes.”
BackgroundOntogeny of Tumor-associated CD4+CD25+Foxp3+ T-regulatory Cells
Li, Q., & Egilmez, N. K. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1220390 · Cited by 9
“Other pairings reported include CCL5/CCR5 (Tan et al., 2009), CXCL12/CXCR4 (Wald et al., 2006; Jaafar et al., 2009; Yan et al., 2011), CCL20/CCR6 (Chen et al., 2011), and CCL28/CCR10 (Facciabene et al. 2011).”
TREG Cells in Cancer: Beyond Classical Immunological Control
Bos, P. D. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1222206 · Cited by 9
“Furthermore, hypoxia-mediated recruitment of TREG cells has been shown to result in tumor angiogenesis in ovarian transplantablemodels (Facciabene et al., 2011).”
BackgroundSun, Y., Su, X., Zhou, R., Wang, D., Yuan, Z., Jiang, Y., Wang, L., & Chen, Y. (2018) · Tetrahedron · doi:10.1016/j.tet.2018.08.030 · Cited by 9
Self-citationNon-Small Cell Lung Cancer: Challenge and Improvement of Immune Drug Resistance
Kong, F., Wang, Z., Liao, D., Zuo, J., Xie, H., Li, X., & Jia, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739191 · Cited by 10
Li, F., Shao, X., Liu, D., Jiao, X., Yang, X., Yang, W., & Liu, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091809 · Cited by 10
Hu, B., Qu, C., Qi, W.-J., Liu, C., & Xiu, D. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.955673 · Cited by 9
“Notably, in the setting of HCC, hypoxia-induced chemokine (C-C pattern) ligand 28 (CCL28) promotes Treg recruitment, leading to enhanced angiogenesis and VEGF expression (Facciabene et al., 2011; Ren et al., 2016).”
BackgroundImmune Cell Metabolism and Immuno-Oncology
Patel, C. H., & Powell, J. D. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-042605 · Cited by 11
An RNA-seq-Based Expression Profiling of Radiation-Induced Esophageal Injury in a Rat Model
Sun, Z., Li, J., Lin, M., Zhang, S., Luo, J., & Tang, Y. (2019) · Dose-Response · doi:10.1177/1559325819843373 · Cited by 9
CAR-armed cell therapy for gliomas.
Zhai, Y., Li, G., Jiang, T., & Zhang, W. (2019) · PubMed · Cited by 9
Tissue-Resident Lymphocytes: Implications in Immunotherapy for Hepatocellular Carcinoma
Han, J. W., & Yoon, S. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010232 · Cited by 9
“In addition, intratumoral Treg cells can produce VEGF, which is associated with tumor angiogenesis [55] and TOX-mediated T cell exhaustion [79] in other cancers.”
BackgroundCCL22 and CCL26 are potential biomarkers for predicting distant metastasis in thyroid carcinoma
Tong, J., Jiang, W. J., Zhang, X., Wang, R., Qiao, T., Song, Y., Gao, D., Yu, X., Lv, Z., & Li, D. (2022) · Journal of International Medical Research · doi:10.1177/03000605221139555 · Cited by 9
Kunz, P., Fellenberg, J., Moskovszky, L. E., Sápi, Z., Krenács, T., Poeschl, J., Lehner, B., Szendrői, M., Ewerbeck, V., Kinscherf, R., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090727 · Cited by 9
Huang, B., Yin, M., Li, X., Cao, G., Qi, J., Lou, G., Sheng, S., Kou, J., Chen, K., & Yu, B. (2016) · Oncotarget · doi:10.18632/oncotarget.8487 · Cited by 9
“EOC cells have high tolerance to low oxygen, which enables them to evade chemotherapy and rapidly develop drug resistance [8].”
Understanding and Targeting Human Cancer Regulatory T Cells to Improve Therapy
Kolb, H. R., Borcherding, N. C., & Zhang, W. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6407-9_12 · Cited by 12
Oxygen and metabolic reprogramming in the tumor microenvironment influences metastasis homing
Bisht, V. S., Giri, K., Kumar, D., & Ambatipudi, K. (2021) · Cancer Biology & Therapy · doi:10.1080/15384047.2021.1992233 · Cited by 10
Mastrogiovanni, M., Donnadieu, E., Pathak, R., & Bartolo, V. D. (2024) · Biology · doi:10.3390/biology13110860 · Cited by 10
“In addition to the PD-L1 checkpoint stimulation, TME hypoxia also promotes immune escape through various other mechanisms, as reported elsewhere [118–121].”
Yang, K., Chen, H., Lyu, Y., Wei, W., Wei, X., Ling, Y., Lin, B., Zhou, G., Chen, J., Shi, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64283-4 · Cited by 10
Synergistic effects of radiotherapy and immunotherapy: improving oncological outcomes
Chen, X., Liu, W., Wang, Y., Yue, Z., Wang, J., Liu, Y., Xu, L., & Hu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771355 · Cited by 15
“These pathways collectively reduce antigen presentation, impair cytotoxic T-cell traf fi cking, and limit ICI responsiveness (114 – 116).”
Regulatory T cells in cancer and inflammation
Yang, H., Zhang, H., Xia, N., & Cheng, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02584-w · Cited by 12
Qin, H., Sun, R., Guo, X., Fang, L., Xu, M., Teng, Y., Ning, Z., Wang, A., & Liu, J. (2023) · Aging · doi:10.18632/aging.204528 · Cited by 14
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.